When will edarbi go generic?

What happens when Edarbi's patent expires?

Edarbi, also known as azilsartan medoxomil, is a medication used to treat high blood pressure. The patent for Edarbi was held by Takeda Pharmaceuticals and Daiichi Sankyo, but it has since expired [1].

How does generic entry work?

Once a patent expires, generic manufacturers can file an Abbreviated New Drug Application (ANDA) with the FDA to produce and sell a generic version of the medication. The FDA reviews the ANDA to ensure that the generic drug is bioequivalent to the original brand-name drug [2].

When will Edarbi go generic?

According to DrugPatentWatch.com, the patent for Edarbi is set to expire in 2026 in the United States [3]. However, this date may be subject to change due to various factors, including patent extensions, litigations, or new developments.

Who makes generic Edarbi?

Several generic manufacturers have filed ANDA for Edarbi with the FDA, including Mylan and Teva Pharmaceuticals. These companies will be eligible to market and sell generic versions of Edarbi once the patent expires.

What does this mean for consumers?

Generic entry can lead to significant cost savings for consumers. Once generic Edarbi becomes available, the prices of both brand-name and generic versions of the medication should decrease, making treatment options more accessible to those with high blood pressure.

References:

[1] [Link:https://www.drugpatentwatch.com/drugs/edarbi-azilsartan-medoxomil]
[2] [FA] https://www.fda.gov/patents/abbreviated-new-drug-applications-anda]
[3] [DrugPatentWatch.com, "Edarbi: 2026 Patent Expiration Date" ]